Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1996 1
1997 1
1999 1
2000 1
2005 1
2007 1
2009 1
2010 3
2011 3
2012 6
2013 1
2014 2
2015 11
2016 16
2017 21
2018 20
2019 31
2020 35
2021 45
2022 45
2023 44
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of Short- and Long-Term Outcomes After Resection in Patients with Locally Advanced versus (Borderline) Resectable Pancreatic Cancer.
Brada LJH, Schouten TJ, Daamen LA, Seelen LWF, Walma MS, van Dam R, de Hingh IH, Liem MSL, de Meijer VE, Patijn GA, Festen S, Stommel MWJ, Bosscha K, Besselink MG, van Santvoort HC, Molenaar IQ; Dutch Pancreatic Cancer Group. Brada LJH, et al. Ann Surg. 2024 Apr 1. doi: 10.1097/SLA.0000000000006289. Online ahead of print. Ann Surg. 2024. PMID: 38557955
SUMMARY BACKGROUND DATA: Selected patients diagnosed with locally advanced pancreatic cancer (LAPC) are increasingly undergoing resection following induction chemotherapy. To evaluate the benefit of this treatment approach, it is helpful to compare outcomes in resec …
SUMMARY BACKGROUND DATA: Selected patients diagnosed with locally advanced pancreatic cancer (LAPC) are increasingly undergoin …
The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative Prediction Model.
Walma M, Maggino L, Smits FJ, Borggreve AS, Daamen LA, Groot VP, Casciani F, de Meijer VE, Wessels FJ, van der Schelling GP, Nieuwenhuijs VB, Bosscha K, van der Harst E, van Dam R, Liem MS, Festen S, Stommel MWJ, Roos D, Wit F, de Hingh IH, Bonsing BA, Busch OR, Groot Koerkamp B, Kazemier G, Besselink MG, Salvia R, Malleo G, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group. Walma M, et al. J Clin Med. 2024 Mar 14;13(6):1679. doi: 10.3390/jcm13061679. J Clin Med. 2024. PMID: 38541904 Free PMC article.
Occult metastases are detected in 10-15% of patients during exploratory laparotomy for pancreatic cancer. This study developed and externally validated a model to predict occult metastases in patients with potentially resectable pancreatic cancer. Mode …
Occult metastases are detected in 10-15% of patients during exploratory laparotomy for pancreatic cancer. This study developed …
Metformin boosts anti-tumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study.
van Eijck CWF, Vadgama D, van Eijck CHJ, Wilmink JW; Dutch Pancreatic Cancer Group (DPCG). van Eijck CWF, et al. J Natl Cancer Inst. 2024 Mar 26:djae070. doi: 10.1093/jnci/djae070. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 38530777
BACKGROUND: Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant exploration in treating pancreatic cancer. This study aimed to investigate the influence of metformin on patient survival and …
BACKGROUND: Beyond demographic and immune factors, metabolic considerations, particularly metformin's recognized impact in oncology, warrant …
Prophylactic abdominal drainage after distal pancreatectomy (PANDORINA): an international, multicentre, open-label, randomised controlled, non-inferiority trial.
van Bodegraven EA, Balduzzi A, van Ramshorst TME, Malleo G, Vissers FL, van Hilst J, Festen S, Abu Hilal M, Asbun HJ, Michiels N, Koerkamp BG, Busch ORC, Daams F, Luyer MDP, Ramera M, Marchegiani G, Klaase JM, Molenaar IQ, de Pastena M, Lionetto G, Vacca PG, van Santvoort HC, Stommel MWJ, Lips DJ, Coolsen MME, Mieog JSD, Salvia R, van Eijck CHJ, Besselink MG; Dutch Pancreatic Cancer Group. van Bodegraven EA, et al. Lancet Gastroenterol Hepatol. 2024 May;9(5):438-447. doi: 10.1016/S2468-1253(24)00037-2. Epub 2024 Mar 16. Lancet Gastroenterol Hepatol. 2024. PMID: 38499019 Clinical Trial.
The primary outcome was the rate of major morbidity (Clavien-Dindo score III), and the most relevant secondary outcome was grade B or C POPF, grading per the International Study Group for Pancreatic Surgery. Outcomes were assessed up to 90 days postoperatively and a …
The primary outcome was the rate of major morbidity (Clavien-Dindo score III), and the most relevant secondary outcome was grade B or C POPF …
Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a nationwide analysis.
Wismans LV, Suurmeijer JA, van Dongen JC, Bonsing BA, Van Santvoort HC, Wilmink JW, van Tienhoven G, de Hingh IH, Lips DJ, van der Harst E, de Meijer VE, Patijn GA, Bosscha K, Stommel MW, Festen S, den Dulk M, Nuyttens JJ, Intven MPW, de Vos-Geelen J, Molenaar IQ, Busch OR, Koerkamp BG, Besselink MG, van Eijck CHJ; Dutch Pancreatic Cancer Group. Wismans LV, et al. Surgery. 2024 Mar 5:S0039-6060(24)00055-2. doi: 10.1016/j.surg.2024.01.029. Online ahead of print. Surgery. 2024. PMID: 38448277 Free article.
METHODS: All patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included in the mandatory nationwide prospective Dutch Pancreatic Cancer Audit (2014-2020). ...The relationship between preoperative chemotherapy, chemoradiothe …
METHODS: All patients after pancreatoduodenectomy for pancreatic ductal adenocarcinoma were included in the mandatory nationwide pros …
The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis.
Schouten TJ, van Goor IWJM, Dorland GA, Besselink MG, Bonsing BA, Bosscha K, Brosens LAA, Busch OR, Cirkel GA, van Dam RM, Festen S, Groot Koerkamp B, van der Harst E, de Hingh IHJT, Intven MPW, Kazemier G, Liem MSL, van Lienden KP, Los M, de Meijer VE, Patijn GA, Schreinemakers JMJ, Stommel MWJ, van Tienhoven GJ, Verdonk RC, Verkooijen HM, van Santvoort HC, Molenaar IQ, Daamen LA; Dutch Pancreatic Cancer Group. Schouten TJ, et al. Ann Surg Oncol. 2024 Feb 22. doi: 10.1245/s10434-024-15070-w. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38386198
BACKGROUND: Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond anatomical criteria, considering both biological and conditional factors. ...PATIENTS AND METHODS: A nationwide observational cohort study …
BACKGROUND: Novel definitions suggest that resectability status for pancreatic ductal adenocarcinoma (PDAC) should be assessed beyond …
Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.
Mackay TM, Latenstein AEJ, Augustinus S, van der Geest LG, Bogte A, Bonsing BA, Cirkel GA, Hol L, Busch OR, den Dulk M, van Driel LMJW, Festen S, de Groot DA, de Groot JB, Groot Koerkamp B, Haj Mohammad N, Haver JT, van der Harst E, de Hingh IH, Homs MYV, Los M, Luelmo SAC, de Meijer VE, Mekenkamp L, Molenaar IQ, Patijn GA, Quispel R, Römkens TEH, van Santvoort HC, Stommel MWJ, Venneman NG, Verdonk RC, van Vilsteren FGI, de Vos-Geelen J, van Werkhoven CH, van Hooft JE, van Eijck CHJ, Wilmink JW, van Laarhoven HWM, Besselink MG; Dutch Pancreatic Cancer Group. Mackay TM, et al. JAMA Surg. 2024 Apr 1;159(4):429-437. doi: 10.1001/jamasurg.2023.7872. JAMA Surg. 2024. PMID: 38353966 Free PMC article. Clinical Trial.
OBJECTIVE: To improve the implementation of guideline-based best practices in the Netherlands in pancreatic cancer care and assess the impact on survival. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, stepped-wedge cluster randomized trial compared enhanced i …
OBJECTIVE: To improve the implementation of guideline-based best practices in the Netherlands in pancreatic cancer care and as …
Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI, Janssen BV, Nio CY, Kop MPM, Kazemier G, Busch OR, Struik F, Marquering HA, Stoker J, Besselink MG, Verpalen IM; Pancreatobiliary and Hepatic Artificial Intelligence Research (PHAIR) consortium. Bereska JI, et al. Eur Radiol Exp. 2024 Feb 12;8(1):18. doi: 10.1186/s41747-023-00419-9. Eur Radiol Exp. 2024. PMID: 38342782 Free PMC article.
Based on these measurements, the model classifies the resectability stage using the Dutch Pancreatic Cancer Group criteria as either resectable, borderline resectable, or locally advanced (LA). ...RELEVANCE STATEMENT: This AI model enables automated va …
Based on these measurements, the model classifies the resectability stage using the Dutch Pancreatic Cancer Group …
Development of pancreatic diseases during long-term follow-up after acute pancreatitis: a post-hoc analysis of a prospective multicenter cohort.
de Rijk F, Sissingh NJ, Boel TT, Timmerhuis HC, de Jong M, Pauw HS, van Veldhuisen CL, Hallensleben ND, Anten M, Brink MA, Curvers WL, van Duijvendijk P, Hazen WL, Kuiken SD, Poen AC, Quispel R, Römkens T, Spanier B, Tan A, Vleggaar FP, Voorburg A, Witteman B, Ali UA, Issa Y, Bouwense S, Voermans RP, van Wanrooij R, Stommel M, van Hooft JE, de Jonge PJ, van Goor H, Boermeester MA, Besselink MG, Bruno MJ, Verdonk RC, van Santvoort HC; Dutch Pancreatitis Study Group. de Rijk F, et al. J Gastroenterol Hepatol. 2024 Apr;39(4):674-684. doi: 10.1111/jgh.16453. Epub 2024 Jan 8. J Gastroenterol Hepatol. 2024. PMID: 38191176
Primary endpoints were recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic cancer. Cumulative incidence calculations and risk analyses were performed. ...RAP and CP occurred in 301 patients (25%) and 72 patients (6%), with the highest incid …
Primary endpoints were recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), and pancreatic cancer. Cumulative incide …
Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy.
Stoop TF, Seelen LWF, van 't Land FR, Lutchman KRD, van Dieren S, Lips DJ, van der Harst E, Kazemier G, Patijn GA, de Hingh IH, Wijsman JH, Erdmann JI, Festen S, Groot Koerkamp B, Mieog JSD, den Dulk M, Stommel MWJ, Busch OR, de Wilde RF, de Meijer VE, Te Riele W, Molenaar IQ, van Eijck CHJ, van Santvoort HC, Besselink MG; Dutch Pancreatic Cancer Group. Stoop TF, et al. Ann Surg Oncol. 2024 Apr;31(4):2640-2653. doi: 10.1245/s10434-023-14650-6. Epub 2023 Dec 17. Ann Surg Oncol. 2024. PMID: 38105377
BACKGROUND: Several international high-volume centers have reported good outcomes after resection of locally advanced pancreatic cancer (LAPC) following chemo(radio)therapy, but it is unclear how this translates to nationwide clinical practice and outcome. ...PATIEN …
BACKGROUND: Several international high-volume centers have reported good outcomes after resection of locally advanced pancreatic c …
256 results